The U.S. Food and Drug Administration on Oct. 27 approved Amgen’s cancer immunotherapy drug Imlygic for use in patients with the most deadly types of skin cancer. Imlygic, which is the first immunotherapy like this to gain approval for use in the U.S., is a genetically modified herpes virus that is designed to replicate itself Read More →
Goleta breast implant developer Sientra said there had been a fire at the factory of its manufacturer in Brazil, the company announced on Oct. 23. Sientra did not say how big the fire was or if it would impact manufacturing at Silimed, the largest producer of silicone implants in South America. The company didn’t specify Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Shares of Sientra hit a new all-time low on Oct. 16 when the stock fell another six cents on the day and closed at $5.77 per share. For the Goleta-based breast implant manufacturer, it marks another low in a saga that’s starting to turn ugly. Shares of Sientra initially plummeted from $20.58 per share to Read More →
Kythera Biopharmaceuticals is permanently laying off 117 employees at its Westlake Village offices, according to a filing today with the Securities and Exchange Commission. The layoffs come as no surprise and appear to be part of Kythera’s merger with Dublin-based Allergan. On June 17, Allergan announced that it would buy Kythera for $2.1 billion. The Read More →
Thousand Oaks-based pharmaceutical giant Amgen announced results Oct. 12 showing its bone density drug Prolia reduced the incidences of bone fractures in post-menopausal women with osteoporosis over 10 years. Prolia is designed to raise bone density in people with a history of osteoporosis. Amgen released the data during the annual conference of the American Society Read More →
Sientra CEO Hani Zeini sent another letter to plastic surgeons to reassure them that its products are safe. Sientra, a Goleta-based breast implant manufacturer, saw shares drop sharply over the past few months from a high of $23.75 on July 23. In recent weeks the stock fell from $20.58 on Sept. 23 to a close Read More →
